Who are Placebo (canagliflozin)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Control Rx, Concomitant therapy 14 days, Dapagliflozin/Pioglitazone, GnP, Dapagliflozin+ACEI treatment, Dapagliflozin + Lobeglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-canagliflozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo (canagliflozin) — Competitive Intelligence Brief

Placebo (canagliflozin) (Placebo (canagliflozin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 (sodium-glucose cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo (canagliflozin) (Placebo (canagliflozin)) — Novo Nordisk A/S. Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo (canagliflozin) TARGET	Placebo (canagliflozin)	Novo Nordisk A/S	phase 3	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Control Rx	Control Rx	National and Kapodistrian University of Athens	marketed	SGLT2 inhibitor
Concomitant therapy 14 days	Concomitant therapy 14 days	Incheon St.Mary's Hospital	marketed	SGLT2 inhibitor	SGLT2
Dapagliflozin/Pioglitazone	Dapagliflozin/Pioglitazone	Boryung Pharmaceutical Co., Ltd	marketed	SGLT2 inhibitor / Thiazolidinedione combination	SGLT2 / PPAR-γ
GnP	GnP	West China Hospital	marketed	SGLT2 inhibitor	SGLT2
Dapagliflozin+ACEI treatment	Dapagliflozin+ACEI treatment	Children's Hospital of Fudan University	marketed	SGLT2 inhibitor + ACE inhibitor combination	SGLT2 and ACE
Dapagliflozin + Lobeglitazone	Dapagliflozin + Lobeglitazone	Seoul National University Bundang Hospital	marketed	SGLT2 inhibitor + thiazolidinedione combination	SGLT2 and PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo (canagliflozin) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-canagliflozin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab